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Genome modification can be used in applications involving either gene disruption or gene correction. 
The desired outcomes of targeted DNA cleavage depend on the objectives of different genome 
modification strategies, but most of them are initiated with a DNA double strand break at a specific 
site. Targeted genome editing is a rapidly emerging field based on the use of rare-cleaving 
endonucleases to specifically target and cleave unique DNA sequences. Researchers in Seattle, 
including Dr. Barry Stoddard of the Basic Sciences Division, have developed a new rare-cleaving 
endonuclease that holds immense promise in addressing some of the main hurdles facing genome 
modification applications. 
The quest to specifically recognize and cleave a DNA sequence safely for therapeutic applications 
requires addressing three main issues confronting this technology. First, enzymes must be designed 
to specifically target the desired DNA sequence with a high efficiency. Second, enzyme specificity 
must be sufficient so that off-target cleavage at similar but non-desired DNA sites, is minimized, as 
off-target activity can lead to cytotoxicity or worse outcomes. Third, current endonuclease platforms 
are either too large, require the delivery of multiple peptide chains, or possess other characteristics 
that result in problems in delivery when using the most common gene therapy delivery vectors. A 
class of new enzymes reported in a recent paper published inNucleic Acids Research, designated 
megaTALs, was designed to improve the technology in all three of these areas. 
MegaTALs are derived from the combination of two distinct classes of DNA targeting enzymes. 
Meganucleases (also referred to as homing endonucleases) are single peptide chains that have the 
advantage of both DNA recognition and nuclease functions in the same domain. However, 
meganuclease target recognition is difficult to modify, and they often have reduced specificity and 
lower on-target cleavage efficiency than other genome targeting endonucleases. Transcription 
activator-like (TAL) effectors are DNA recognizing proteins that have been linked to separate DNA 
endonuclease domains in order to achieve a targeted DNA double strand break. In contrast to 
meganucleases, TALs are easily engineered to target specific DNA sequences. Current platforms 
rely on a pair of TAL effectors, each coupled to a non-specific DNA cleavage domain, in which DNA  
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cleavage only occurs when both TAL effectors bind their respective sequences and the two 
endonuclease domains dimerize in order to cleave the DNA. However, TAL effector nucleases can 
cause off-target activity, are much larger than meganucleases, and require the delivery of two 
separate proteins. A megaTAL is the unification of a TAL effector with a meganuclease. 
Dr. Stoddard is highly optimistic about this new technology. "MegaTALs may possess the best 
combination of properties of any gene targeting protein," he explains. Lead author Dr. Sandrine 
Boissel, member of the Andrew Scharenberg Lab at Seattle Children's Hospital, states, "the major 
advantage of the megaTAL architecture is that it allows us to achieve high rates of DNA modification 
with greater target site specificity than any other available nuclease platform, making it particularly 
useful for gene therapy applications that require minimal off-target cleavage." 
Boissel, Stoddard, and colleagues show the benefits of combining these two platforms in a series 
of in vitro experiments that detect DNA cleavage. The TAL effector binds with high affinity to a DNA 
sequence upstream of the targeted cleavage site and 'addresses' the meganuclease to its 
corresponding DNA sequence. Thus, both cleavage activity and specificity were highly enhanced 
over the meganuclease alone. Furthermore, by increasing the length of the DNA sequence 
recognized by megaTALs compared to meganucleases alone, off-target cleavage was seen to be 
substantially reduced. Finally, the addition of a meganuclease as the DNA cleavage domain avoids 
the requirement of two separate TAL effector protein chains to exert an effect, thus reducing the size 
of the enzyme platform and improving its potential to be adequately delivered, for example via viral 
vector delivery. 
As a glimpse of the potential these new enzymes may have for therapeutic applications, the 
researchers designed a megaTAL to target the T-cell receptor alpha (TCRα) gene. Knockout of the 
TCRα gene in human T-cells could be used to improve the safety of some T cell-based therapies by 
preventing TCRs from generating graft-versus-host disease. The TCRα megaTAL was shown to 
exhibit a ~20-fold increase in activity over the meganuclease alone at targeting the TCRα gene in T-
cells with extremely low off-target cleavage. 
Despite these promising first results, naturally, as with any new development, there remains room for 
improvement with MegaTALs. Dr. Stoddard believes, "their ultimate value and application will 
depend on continued improvements in engineering the specificity of their nuclease domain." 
Similarly, Dr. Boissel sees the potential for "a redesigned interface between the TAL effector and 
meganuclease domains that would force these domains to work cooperatively and thus further 
reduce the level of cleavage activity at off-target sites." 
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Image provided by Dr. Barry Stoddard (Basic Sciences 
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A megaTAL, the fusion of a meganuclease with a TAL effector, 
is a new class of DNA targeting endonucleases with higher 
activity and specificity. 
 
